

GLAXOSMITHKLINE PLC

Form 6-K

April 16, 2019

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 16 April 2019

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No ☒

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms E N Walmsley
b) Position/status Chief Executive Officer

- c) Initial notification/amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019.

- c) Price(s) and volume(s)
Price(s) Volume(s)
£15.5009 1856.065
n/a (single transaction)

Aggregated information

- d) Aggregated volume Price

- e) Date of the transaction 2019-04-15
f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr R G Connor
b) Position/status President, Global Vaccines

- c) Initial notification/amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

- b) Nature of the transaction

Acquisition of Ordinary
Shares following the
re-investment of dividends
paid to shareholders on 11
April 2019.

c) Price(s) and volume(s)	Price(s)	Volume(s)
	£15.5009	835.687
Aggregated information	n/a (single transaction)	
d)	Aggregated volume Price	
e) Date of the transaction	2019-04-15	
f) Place of the transaction	London Stock Exchange (XLON)	

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Ms D Conrad
 - b) Position/status SVP, Human Resources
 - c) Initial notification/amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
--	--

b) Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019.	
c) Price(s) and volume(s)	Price(s)	Volume(s)
	£15.5009	9.069
Aggregated information	n/a (single transaction)	
d)	Aggregated volume Price	
e) Date of the transaction	2019-04-15	
f) Place of the transaction	London Stock Exchange (XLON)	

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr S P Dingemans

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- b) Position/status Executive Director
- c) Initial notification/amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019.

- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|--------------------------|-----------|
| £15.5009 | 0.001 |
| n/a (single transaction) | |

- d) Aggregated information
- Aggregated volume Price

- e) Date of the transaction 2019-04-15
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr J Ford
- b) Position/status SVP & General Counsel

- c) Initial notification/amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W1053

- b) Nature of the transaction Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 April 2019.

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

c) Price(s) and volume(s)	Price(s) \$ 40.8259	Volume(s) 0.002
Aggregated information	n/a (single transaction)	
d) Aggregated volume Price		
e) Date of the transaction	2019-04-12	
f) Place of the transaction	New York Stock Exchange (XNYS)	

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr J Ford
b) Position/status	SVP & General Counsel
c) Initial notification/amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
--	--

b) Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019.
------------------------------	--

c) Price(s) and volume(s)	Price(s) £15.5009	Volume(s) 0.000034
Aggregated information	n/a (single transaction)	

d) Aggregated volume Price	
----------------------------	--

e) Date of the transaction	2019-04-15
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr N Hiron
b) Position/status	SVP, Global Ethics & Compliance
c) Initial notification/amendment	Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
Details of the transaction(s): section to be repeated for (i) each type of
3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
American Depositary Shares
('ADSs')
a) Description of the financial instrument ISIN: US37733W1053
Acquisition of ADSs
following the re-investment
b) Nature of the transaction of dividends paid to
shareholders on 11 April
2019
c) Price(s) and volume(s) Price(s) Volume(s)
\$ 40.8259 22.812
n/a (single transaction)
Aggregated information
d) Aggregated volume Price
e) Date of the transaction 2019-04-12
f) Place of the transaction New York Stock Exchange
(XNYS)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr N Hiron
b) Position/status SVP, Global Ethics &
Compliance
c) Initial notification/amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
Details of the transaction(s): section to be repeated for (i) each type of
3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
Ordinary shares of 25 pence
each ('Ordinary Shares')
a) Description of the financial instrument ISIN: GB0009252882

- Acquisition of Ordinary
Shares following the
b) Nature of the transaction re-investment of dividends
paid to shareholders on 11
April 2019.
c) Price(s) and volume(s) Price(s) Volume(s)
£15.5009 839.365

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Aggregated information	n/a (single transaction)
d) Aggregated volume Price	
e) Date of the transaction	2019-04-15
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr D Jackson
PCA of Ms S Jackson (SVP, Global Communications and CEO Office)
 - b) Position/status
 - c) Initial notification/amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882				
b) Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019.				
c) Price(s) and volume(s)	<table border="0"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>£15.5009</td> <td>73.793</td> </tr> </table>	Price(s)	Volume(s)	£15.5009	73.793
Price(s)	Volume(s)				
£15.5009	73.793				

Aggregated information	n/a (single transaction)
d) Aggregated volume Price	
e) Date of the transaction	2019-04-15
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mrs S Jackson
SVP, Global Communications and CEO Office
 - b) Position/status

c) Initial notification/amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019.

c) Price(s) and volume(s) Price(s) Volume(s)
£15.5009 112.492
n/a (single transaction)

d) Aggregated information
Aggregated volume Price

e) Date of the transaction 2019-04-15

f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr B McNamara
CEO, GSK Consumer Healthcare

b) Position/status

c) Initial notification/amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W1053

b) Nature of the transaction Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 April 2019

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

c) Price(s) and volume(s)	Price(s) \$ 40.8259	Volume(s) 947.143
Aggregated information	n/a (single transaction)	
d) Aggregated volume Price		
e) Date of the transaction	2019-04-12	
f) Place of the transaction	New York Stock Exchange (XNYS)	

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr D Redfern
b) Position/status	Chief Strategy Officer
c) Initial notification/amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
--	--

b) Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019.
------------------------------	--

c) Price(s) and volume(s)	Price(s) £15.5009	Volume(s) 3072.811
Aggregated information	n/a (single transaction)	

d) Aggregated volume Price

e) Date of the transaction	2019-04-15
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr R Simard
b) Position/status	President, Pharma Supply Chain
c) Initial notification/amendment	Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019.
c) Price(s) and volume(s) Price(s) Volume(s)
£15.5009 590.721
Aggregated information n/a (single transaction)
d) Aggregated volume Price
e) Date of the transaction 2019-04-15
f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr P C Thomson
b) Position/status President, Global Affairs
c) Initial notification/amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019.
c) Price(s) and volume(s) Price(s) Volume(s)
£15.5009 706.619

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Aggregated information	n/a (single transaction)
d) Aggregated volume Price	
e) Date of the transaction	2019-04-15
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mrs K Thomson PCA of Mr P C Thomson
b) Position/status	(President, Global Affairs)
c) Initial notification/amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

3.	Ordinary shares of 25 pence each ('Ordinary Shares')				
a) Description of the financial instrument	ISIN: GB0009252882				
b) Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019.				
c) Price(s) and volume(s)	<table border="0"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>£15.5009</td> <td>154.042</td> </tr> </table>	Price(s)	Volume(s)	£15.5009	154.042
Price(s)	Volume(s)				
£15.5009	154.042				
Aggregated information	n/a (single transaction)				
d) Aggregated volume Price					
e) Date of the transaction	2019-04-15				
f) Place of the transaction	London Stock Exchange (XLON)				

SIGNATURES

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: April 16, 2019

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc